CINECA IRIS Institutional Research Information System

ROMEI, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.305
EU - Europa 5.036
AS - Asia 1.573
AF - Africa 261
SA - Sud America 31
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.215
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.145
IT - Italia 1.938
DE - Germania 1.039
SE - Svezia 870
CN - Cina 703
SG - Singapore 409
BG - Bulgaria 314
GB - Regno Unito 283
CI - Costa d'Avorio 189
CA - Canada 151
TR - Turchia 131
AT - Austria 127
VN - Vietnam 124
IN - India 112
UA - Ucraina 101
FI - Finlandia 96
RU - Federazione Russa 89
SN - Senegal 64
CH - Svizzera 44
HK - Hong Kong 37
FR - Francia 26
BR - Brasile 24
BE - Belgio 23
NL - Olanda 17
JP - Giappone 14
CZ - Repubblica Ceca 13
GR - Grecia 13
IR - Iran 11
PL - Polonia 10
AU - Australia 6
CR - Costa Rica 6
IL - Israele 6
RO - Romania 6
ID - Indonesia 5
PK - Pakistan 5
ES - Italia 4
HU - Ungheria 4
IE - Irlanda 4
RS - Serbia 4
TW - Taiwan 4
CL - Cile 3
EU - Europa 3
KR - Corea 3
MX - Messico 3
PE - Perù 3
SK - Slovacchia (Repubblica Slovacca) 3
BH - Bahrain 2
BJ - Benin 2
DK - Danimarca 2
EE - Estonia 2
EG - Egitto 2
IQ - Iraq 2
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
DZ - Algeria 1
GE - Georgia 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
PT - Portogallo 1
SA - Arabia Saudita 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 14.215
Salva come PNG Salva come JPEG
Città #
Fairfield 815
Woodbridge 784
Ann Arbor 689
Chandler 614
Houston 545
Ashburn 476
Seattle 340
Cambridge 318
Milan 315
Sofia 313
Wilmington 272
Beijing 216
Abidjan 189
Singapore 186
New York 185
Serra 153
Boardman 145
Princeton 143
Santa Clara 139
Ottawa 135
Jacksonville 121
Vienna 118
Lawrence 116
Medford 96
Pisa 89
Florence 88
Des Moines 81
Rome 80
London 69
Nanjing 68
Dearborn 65
Izmir 65
Dakar 64
Dong Ket 56
Boulder 54
Istanbul 54
Bremen 53
Shanghai 52
Frankfurt am Main 49
Redwood City 42
Naples 41
San Diego 41
Munich 39
Lancaster 38
Bern 37
Fuzhou 36
Washington 33
Hong Kong 32
Dallas 27
Bologna 24
Redmond 24
Grafing 23
Ogden 22
Changsha 21
Nanchang 21
Shenyang 21
Brussels 20
Jüchen 20
Los Angeles 19
Quanzhou 17
Kunming 16
Tianjin 16
Hebei 15
Hangzhou 14
Palermo 14
Parma 14
Bengaluru 13
Hefei 13
Jiaxing 13
Norwalk 13
Pune 13
Verona 13
Genoa 12
Mumbai 12
Wuhan 12
Chiesina Uzzanese 11
Helsinki 11
Jaboatão 11
Nürnberg 11
Phoenix 11
Napoli 10
Sacile 10
Trieste 10
Turin 10
Bhavnagar 9
Düsseldorf 9
Lucca 9
Guangzhou 8
Kocaeli 8
Bari 7
Chengdu 7
Cuneo 7
Jinan 7
Montale 7
Salerno 7
Cascina 6
Detroit 6
Indiana 6
La Spezia 6
Messina 6
Totale 9.421
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 855
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 262
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 197
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 191
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 178
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 174
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 169
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 166
Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 165
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 164
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 161
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 159
null 157
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 156
Targeted Therapy in Thyroid Cancer: State of the Art 156
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 152
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 150
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 148
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 146
null 146
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. 144
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 143
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 143
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma 142
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. 141
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer 138
RET point mutations in Thyroid Carcinoma 138
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 138
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. 137
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 137
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 136
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. 134
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 132
Genome-wide association study on differentiated thyroid cancer. 132
Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma 131
A comprehensive meta-analysis of case-control association studies to evaluate polymorphisms associated with the risk of differentiated thyroid carcinoma 130
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 130
Inherited variants in genes somatically mutated in thyroid cancer 126
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 125
Post-surgical follow-up of differentiated thyroid cancer. 122
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 122
null 122
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 121
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 119
Correlazione genotipo-fenotipo nelle MEN 2: stato dell’arte dopo 15 anni di conoscenze 118
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 118
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 117
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 116
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. 115
Genetic and clinical features of multiple endocrine neoplasia types 1 and 2 115
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 115
null 114
Obesity and the Risk of Papillary Thyroid Cancer: A Pooled Analysis of Three Case-Control Studies. 112
The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans 112
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 111
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 111
Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma 111
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. 110
Multiple Endocrine Neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 110
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 109
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 107
Ruolo putativo di H4 come gene oncosoppressore nella patogenesi del carcinoma papillare della tiroide 106
Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk 105
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 104
Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: European comments to the guidelines of the American Thyroid Association 104
RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population 103
Correction: Inherited variants in genes somatically mutated in thyroid cancer 102
Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience 101
null 99
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 97
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas 96
Prevalenza di mutazioni di BRAF e riarrangiamenti RET/PTC e TRK in una serie di carcinomi papillari della tiroide 95
Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype 95
RET/PTC rearrangements in thyroid nodules: Studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults 95
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders 92
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 91
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 91
RET proto-oncogene mutations in thyroid carcinomas: clinical relevance 90
RET /PTC translocations and clinico-pathological features in human papillary thyroid carcinoma 89
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 89
NIS mRNA and protein expression in thyroid and non thyroid carcinoma 88
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 88
Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1 86
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 86
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 86
Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis 85
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 85
Pro64His (rs4644) polymorphism within galectin-3 is a risk factor of differentiated thyroid carcinoma and affects the transcriptome of thyrocytes engineered via CRISPR/Cas9 system 85
null 84
Incidental occurrence of metastatic medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 1 carrying germline MEN1 and somatic RET mutations 84
Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association 82
Medullary thyroid carcinoma in children 81
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases 81
Runs of homozygosity and inbreeding in thyroid cancer 81
Transfection with the cDNA of the human thyrotropin receptor of a poorly differentiated rat thyroid cell line (FRT). 78
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 77
Il ciglitazone induce inibizione della crescita in cellule di carcinoma midollare della tiroide (TT) verosimilmente dovuta ad un aumentata espressione di PPAR gamma 76
L’ mRNA dei recettori per HGF e EGF (c-Met e EGFR) e’ iperespresso nei tumori papillari della tiroide 76
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma 76
null 75
Totale 12.640
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.119
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.119
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.856 0 0 0 0 282 310 269 194 225 210 303 63
2020/20211.135 116 85 92 43 72 81 104 93 119 86 63 181
2021/20221.566 59 84 33 103 328 184 46 79 76 61 115 398
2022/20232.518 285 384 185 190 218 266 56 196 485 43 164 46
2023/20241.819 184 169 216 125 212 260 133 104 67 55 110 184
2024/2025926 72 210 91 329 224 0 0 0 0 0 0 0
Totale 14.537